Jean-Marie Cuillerot, M.D., has been appointed chief medical officer of Agenus Inc. Dr. Cuillerot initially joined Agenus in 2016 as VP and Global Head of Clinical Development.
David A. Spiegel, M.D., Ph.D., is now CEO of Kleo Pharmaceuticals Inc.
The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
The Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.
Here are five company stocks that some industry analysts say are under the radar and/or could be a great bargain in 2016 per BioSpace.com sources …
Massachusetts and California have been well-known as biotech hubs for quite some time. Now New York City is seeing a surge in bio company activity.
Immunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.
A listing of the top 20 pharma/biotech companies ranked by DTC spending in 2015.
Fredrik Wiklund has been made chief operating officer of Bioniz Therapeutics Inc.
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
